[{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Ergomed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GS-248","moa":"||mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gesynta Pharma \/ Ergomed","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Pharma \/ Ergomed"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GS-248","moa":"||mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gesynta Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"CTC Clinical Trial Consultants | Research Institutes of Sweden","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GS-248","moa":"||mPGES-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Gesynta Pharma \/ CTC Clinical Trial Consultants | Research Institutes of Sweden","highestDevelopmentStatusID":"6","companyTruncated":"Gesynta Pharma \/ CTC Clinical Trial Consultants | Research Institutes of Sweden"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Hadean Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"GS-248","moa":"||mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gesynta Pharma \/ Hadean Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Pharma \/ Hadean Ventures"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BI 1029539","moa":"||mPGES-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gesynta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gesynta Pharma \/ Inapplicable"}]